Vertex Gets Europe OK for Kaftrio Combination in Cystic Fibrosis
August 21 2020 - 9:46AM
Dow Jones News
By Colin Kellaher
Vertex Pharmaceuticals Inc. on Friday said the European
Commission approved Kaftrio in combination with ivacaftor to treat
people ages 12 and over with cystic fibrosis.
The Boston drug maker said the approval covers the combination
in patients with one F508del mutation and one minimal function
mutation, or two F508del mutations in the cystic fibrosis
transmembrane conductance regulator gene.
The European Medicines Agency's Committee for Medicinal Products
for Human Use in June recommended approval of the combination.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 21, 2020 09:31 ET (13:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024
